IBOGF (Universal Ibogaine) Liabilities-to-Assets : 0.93 (As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Universal Ibogaine Liabilities-to-Assets?

Universal Ibogaine IBOGF +2.14% Liabilities-to-Assets is 0.93 as of Apr. 2025.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Universal Ibogaine's Total Liabilities for the quarter that ended in Apr. 2025 was $2.67 Mil. Universal Ibogaine's Total Assets for the quarter that ended in Apr. 2025 was $2.87 Mil. Therefore, Universal Ibogaine's Liabilities-to-Assets Ratio for the quarter that ended in Apr. 2025 was 0.93.

Universal Ibogaine  (OTCPK:IBOGF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Universal Ibogaine Liabilities-to-Assets Related Terms

Universal Ibogaine Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Liabilities-to-Assets Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Liabilities-to-Assets
Get a 7-Day Free Trial 0.19 1.00 0.38 0.68 0.78

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.78 0.84 0.91 0.93

IBOGF vs LABT, CALC, LNAI: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Universal Ibogaine's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Liabilities-to-Assets falls into.


Universal Ibogaine Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Universal Ibogaine's Liabilities-to-Assets Ratio for the fiscal year that ended in Jul. 2024 is calculated as:

Liabilities-to-Assets (A: Jul. 2024 )=Total Liabilities/Total Assets
=2.568/3.291
=0.78

Universal Ibogaine's Liabilities-to-Assets Ratio for the quarter that ended in Apr. 2025 is calculated as

Liabilities-to-Assets (Q: Apr. 2025 )=Total Liabilities/Total Assets
=2.671/2.866
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.93 mean?
Universal Ibogaine (IBOGF) has a Liabilities-to-Assets of 0.93 as of Apr. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Liabilities-to-Assets too high?
Universal Ibogaine's current Liabilities-to-Assets is 0.93.
How does Universal Ibogaine's Liabilities-to-Assets compare to LABT and CALC?
Universal Ibogaine's Liabilities-to-Assets of 0.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Liabilities-to-Assets is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Liabilities-to-Assets of 0.93. The current Liabilities-to-Assets is 0.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Liabilities-to-Assets is 0.93 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.